Biophytis Files Amendment to Extend OBA Study Pairing BIO101 with Semaglutide

What Happened

Biophytis, a French clinical-stage biotechnology company, has filed a protocol amendment to extend the timeline of OBA, its Phase 2 trial testing the oral drug candidate BIO101 in adults with obesity who are starting treatment with the GLP-1 receptor agonist semaglutide. The filing, reported in regulatory channels in September 2026, indicates the 164-patient study will take longer than originally planned to read out. OBA is among the first dedicated clinical programs to pair a muscle-preserving candidate with a GLP-1 — a combination strategy that has drawn intense interest as weight-loss medicine grapples with lean-mass loss.

Who Is Affected

• Biophytis and its shareholders — the extension pushes spending and data timelines further out on the company's flagship obesity program.
• Obesity and sarcopenia researchers — the trial's design directly addresses whether muscle strength can be protected during rapid GLP-1-associated weight loss.
• Clinicians prescribing GLP-1s — adjunct candidates like BIO101 could eventually define a new standard-of-care pairing.
• Research buyers of metabolic peptides — a validated muscle-preserving adjunct would change how body-composition outcomes are discussed across the field.

Timeline

• 2020–2022 — BIO101, an oral formulation of the plant-derived 20-hydroxyecdysone, is studied in the SARA-INT Phase 2 sarcopenia trial and in hospitalized COVID-19 patients.
• 2025 — OBA is designed as a Phase 2 obesity trial; regulatory go-aheads are secured in the United States and Europe.
• 2026 — Brazil's ANVISA authorizes the trial, published in the country's Federal Official Gazette, expanding the study into a high-prevalence obesity market.
• September 2026 — Biophytis files an amendment to extend the study's conduct, signaling recruitment and operational timelines are taking longer than first planned.

What This Means for Researchers

OBA's primary endpoint is knee-extension strength measured with isokinetic dynamometry — a hard, function-relevant readout rather than a scale number. Participants receive semaglutide as background therapy and are randomized to BIO101 or placebo for 21 weeks, with the company also tracking lean body mass and health-related quality of life. According to the company, BIO101 acts on the protective arm of the renin-angiotensin system and supports mitochondrial function. For the broader research community the message is structural: the next wave of obesity therapeutics is being designed as GLP-1 adjuncts, and trial designs like OBA are the template regulators will see again and again. A timeline extension before data readout is common in multi-country studies — it delays the answer, but it does not change the question.

How to Verify Your Peptides

If you source GLP-1 research materials while studies like this unfold, treat every batch as unverified until tested:

• Our overview of how peptide testing works covers identity, purity, and fill-weight basics.
• The semaglutide purity and COA verification guide explains what a legitimate certificate of analysis should contain.
• An independent third-party testing lab can confirm whether material is what the label claims.

Safe Alternatives

Our evidence-based compound profiles for semaglutide and tirzepatide summarize what the published trials show, and our vendor directory ranks suppliers by transparency signals such as published third-party batch testing.

Sources

• Regulatory announcements (clinical trial registry records and Brazilian Federal Official Gazette notices, 2025–2026)
• Industry reports (September 2026)